Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) is a progressive disease that damages the macula, the part of the retina responsible for sharp, central vision. Several treatments exist, including intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs like Lucentis and Avastin, laser photocoagulation, and photodynamic therapy with Verteporfin. These therapies aim to slow or halt the progression of AMD and preserve vision. In some cases, surgery like a macular translocation or vitrectomy may be necessary.
Age-Related Macular Degeneration (AMD) treatment in Australia involves intravitreal injections of anti-VEGF agents such as Lucentis or Eylea to slow down the progression of the disease. Regular monitoring is necessary.
Australia's public healthcare system may cover some costs, but out-of-pocket expenses can be high. Subsidies are available for those with a concession card.